From 100 Hours to 1 Hour: FDA Dramatically Simplifies its Compassionate Use Process
In response to repeated criticism that terminally ill patients find it too difficult to obtain access to experimental and potentially life-saving drugs, the U.S. Food and Drug Administration (FDA) has announced changes to its “compassionate use” process in the hopes of making it easier for physicians to request access to medical products on behalf of their patients.